Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 6/20 | 0.46 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HRH2 | P25021 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10930120 | 0.99 | HTR7 (0.47) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL1569359 | 0.98 | HTR7 (0.50) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL2058761 | 0.90 | HRH1 (0.57) | HTR7HRH3BCL2BAK1HRH1 | |
| Hydrochloric Acid SCHEMBL10930701 | 0.89 | HRH1 (0.58) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL219876 | 0.88 | HRH1 (0.59) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL7633647 | 0.88 | HTR7 (0.53) | HTR7HRH3TDP1KDM4EMEN1 | |
| SCHEMBL10932211 | 0.87 | HRH3 (0.48) | HTR7HRH3TDP1DRD3KDM4E | |
| Hydrochloric Acid SCHEMBL219199 | 0.87 | HRH1 (0.60) | HTR7HRH3BCL2BAK1HRH1 | |
| Hydrochloric Acid SCHEMBL5686168 | 0.87 | HRH1 (0.60) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL10928076 | 0.87 | TACR1 (0.48) | HTR7HRH3TDP1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469009-B1 | MIXTURE CONSISTING ESSENTIALLY OF PSEUDOEPHEDRINE AND COMPOUND SELECTED FROM 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACID OR AMIDE DERIVATIVES, THEIR INDIVIDUAL OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS | UCB, S.A. (BE) | 2002-10-22 | — | — | US | claimed |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | UCB PHARMA, S.A. (BE) | 2001-09-06 | — | — | US | claimed |
| US-6489329-B2 | MIXTURE OF PSEUDOEPHEDRINE AND 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)ACETIC ACID | UCB S.A. (BE) | 2002-12-03 | — | — | US | disclosed |
| US-6469009-B1 | MIXTURE CONSISTING ESSENTIALLY OF PSEUDOEPHEDRINE AND COMPOUND SELECTED FROM 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACID OR AMIDE DERIVATIVES, THEIR INDIVIDUAL OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS | UCB, S.A. (BE) | 2002-10-22 | — | — | US | disclosed |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | UCB PHARMA, S.A. (BE) | 2001-09-06 | — | — | US | disclosed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | disclosed |
| EP-0058146-B1 | 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACIDS AND THEIR AMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | U C B, S.A. (BE) | 1984-06-27 | — | — | EP | disclosed |
| EP-0058146-A1 | 2-(4-(Diphenylmethyl)-1-piperazinyl)-acetic acids and their amides, process for their preparation and pharmaceutical compositions | U C B, S.A. (BE) | 1982-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | HRH4, HRH2, HRH1 | HTR7 45/4885HRH3 4/4885BCL2 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.